Aspire Universal has launched a $300 million fund through its venture arm to invest in technology to support precision medicine. Penn Medicine Lancaster General Health, a health system, is a general partner in the fund, according to an emailed statement from Aspire. The Aspire Ventures Precision Medicine Fund builds on a pre-existing collaboration between Aspire Ventures, Lancaster General Health, and Capital BlueCross to start Smart Health Innovation Lab, which was formed last year.